News & Media

MEDIAN Technologies to Highlight Value of Imaging Biomarkers at the 2012 ASCO Annual Conference

31 May 2012, Sophia Antipolis, France

MEDIAN Technologies (ALMDT), a leading medical imaging software developer and service provider for oncology clinical trials, announced today its participation in the 2012 ASCO annual conference, to be held next June 1-5, in Chicago, IL, USA.

During ASCO, the world’s premier oncology conference, representatives from MEDIAN will be available to discuss their abstract, ‘Reliability of Imaging Biomarkers for Response Assessment in Advanced Lung Cancer: Influence of Expertise and Automation.’ MEDIAN’s scientific and business development teams will be present at booth 22089 to give demonstrations of their Lesion Management Solutions (LMS) software.

ASCO’sannual meeting will be the occasion for MEDIAN Technologies to officially announce the operational launch of their alliance with Quintiles, the world’s leading biopharmaceutical services organization, to the biopharmaceutical industry and the clinical investigator community.

The Oncology focused alliance agreement between MEDIAN Technologies and Quintiles is designed to provide biopharma customers and clinical investigators with better quality data, increased productivity, faster go/no-go decisions, and, ultimately, more robust regulatory submissions.

“For the past three months we have been creating a highly efficient, integrated operational alliance to deliver what we believe is a truly differentiated medical imaging service to the biopharma industry,” said Fredrik Brag, MEDIAN’s Chief Executive Officer. “Working with Quintiles broadens the scope of clinical trials using our imaging technology to the global level, resulting in better outcomes for today’s patients.”

Today, the ability to gather, share, interpret and sort through medical image data is at the very heart of how cancer therapies and potential cures are being developed and evaluated. But the inherent complexity of managing imaging-based trials across multiple sites introduces many complex challenges, some of which threaten the value of imaging. MEDIAN has set out to change the paradigm for imaging in oncology trials by applying new technology-based solutions to frequently-observed issues related to image interpretation and management: most notably, high rates of variability in data interpretation and a rising complexity in imaging workflows.

About Median Technologies.

Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.

Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.

Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.

“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”

Contacts

MEDIAN Technologies

Fredrik Brag
CEO
+33 4 92 90 65 82
fredrik.brag@mediantechnologies.com

Actifin (Investors)

Ghislaine Gasparetto
+33 1 56 88 11 11
ggasparetto@actifin.fr

Alizé RP (Press)

Caroline Carmagnol
Wendy Rigal

+33 1 44 54 36 66
median@alizerp.com

Cookies help us deliver our services. By using our services, you agree to our use of cookies.